ClinicalTrials.gg
RecruitingNCT07039578Updated Nov 26, 2025

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

A Phase 2 interventional study of CM336 Injection(Low dose group) and CM336 Injection(High dose group) in Primary Light-Chain Amyloidosis, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Amyloidosis with a site in China — 21 open to participants now, 25 under way, 3 of them phase 3. Amyloidosis · China.

Planned enrollment
7th of 24
90 · median 53
Started
2025
with 7 others
Phase 2
7 of 32
3 open now
Primary completion
2026-06
later than 6 of 24 live
Registered
20th of 32
by date

Among the 32 studies in Amyloidosis with a site in China, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is one of 8 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 6 of the 24 other live ones, and was the 20th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

21 of the 32 studies in Amyloidosis with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Amyloidosis with a site in China, or all of them as a file.
02

Study summary

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis

03

Conditions studied

  • Primary Light-Chain Amyloidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary provision of written and ability to comply with protocol requirements.
  • Age ≥18 years, any gender.
  • (ECOG) Performance Status of 0 to 2.
  • Confirmed diagnosis of primary light-chain (AL) amyloidosis.
  • primary AL amyloidosis.
  • Measurable hematologic disease at screening (per protocol-defined criteria).
  • Involvement of ≥1 amyloid-affected organ.
  • Adequate organ function meeting all protocol-specified criteria within 3 days prior to first dose.

Exclusion criteria

Exclusion Criteria:

  • Current or prior diagnosis of multiple myeloma.
  • Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose.
  • cardiovascular or cerebrovascular disease.
  • Any active or uncontrolled infection meeting protocol-defined criteria.
  • Any other condition deemed by the Investigator to preclude safe study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Low dose group(CM336)

    Biological: CM336 Injection(Low dose group)

  • Experimental
    High dose group(CM336)

    Biological: CM336 Injection(High dose group)

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy after CM336 treatment

    Hematologic complete response (hCR) rate

    Time frame: up to 3 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2026, 11 months after the start.

Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 26, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jul 31, 2029
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07039578
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Jul 25, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Nov 26, 2025

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Jian Li
principal investigator · Peking Union Medical College Hospital
Gang An
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CM336

Start the discussion